|
|
|
|
Vol. 61, Issue 6, 1489-1495, June 2002
-D-Arabinofuranosylcytosine
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts (D.R., S.Ku., S.Kh., D.K.); and Lovelace Respiratory Research Institute, Albuquerque, New Mexico (N.M., S.S.)
| |
Abstract |
|---|
|
|
|---|
The response of myeloid leukemia cells to treatment with
1-
-D-arabinofuranosylcytosine (ara-C) includes
activation of the c-Abl protein tyrosine kinase and the
stress-activated protein kinase (SAPK). The present studies demonstrate
that treatment of human U-937 leukemia cells with ara-C is associated
with translocation of SAPK to mitochondria. STI571 (imatinib mesylate),
an inhibitor of c-Abl, blocked both activation and mitochondrial
targeting of SAPK in the ara-C response. In concert with these effects
of STI571, similar findings were obtained in c-Abl-deficient cells. The results further show that STI571 inhibits ara-C-induced loss of
mitochondrial transmembrane potential, caspase-3 activation, and
apoptosis. These findings demonstrate that STI571 down-regulates c-Abl-mediated signals that target the mitochondria in the apoptotic response to ara-C.
| |
Introduction |
|---|
|
|
|---|
The
cellular response to 1-
-D-arabinofuranosylcytosine
(ara-C) and other genotoxic agents includes activation of the
stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (Saleem
et al., 1995
; Chen et al., 1996
; Verheij et al., 1996
; Zanke et al.,
1996
). SAPK phosphorylates and activates the c-Jun, ATF2, and Elk1
transcription factors (Derijard et al., 1994
; Kyriakis et al., 1994
;
Gupta et al., 1995
; Whitmarsh et al., 1995
). These results and the
demonstration that DNA damage is associated with activation of early
response gene expression (Kharbanda et al., 1991
, 1993
; Datta et al.,
1992
) have suggested that SAPK regulates gene transcription as one
response to genotoxic stress. Studies have also shown that SAPK
activation is associated with the apoptotic response to DNA-damaging
agents (Chen et al., 1996
; Verheij et al., 1996
; Zanke et al., 1996
; Kharbanda et al., 2000b
). Moreover, treatment of cells with ionizing radiation is associated with translocation of SAPK to mitochondria, interaction of SAPK with the antiapoptotic Bcl-xL protein, and thereby,
induction of apoptosis (Kharbanda et al., 2000b
). These findings have
supported roles for SAPK in transducing both nuclear and mitochondrial
signals in the cellular response to genotoxic stress.
Ara-C and other genotoxic agents activate a nuclear complex that
consists in part of the c-Abl and Lyn tyrosine kinases (Kharbanda et
al., 1994
, 1995b
; Yuan et al., 1995
). c-Abl binds to the p53 tumor
suppressor in the response to DNA damage (Yuan et al., 1996a
,b
) and
regulates p53 by preventing its nuclear export (Sionov et al., 2001
).
c-Abl also interacts with the p73 homolog of p53 in the apoptotic
response to DNA damage (Agami et al., 1999
; Gong et al., 1999
; Yuan et
al., 1999
). Activated forms of c-Abl confer induction of SAPK activity
and induction of early response gene expression (Sanchez et al., 1994
;
Kharbanda et al., 1995a
; Raitano et al., 1995
). In the DNA-damage
response, nuclear c-Abl activates MEK kinase 1 (MEKK-1) and thereby the
SEK1
SAPK pathway (Kharbanda et al., 1995a
,b
; 2000
). In addition,
c-Abl-deficient cells exhibit a defective SAPK response to
DNA-damaging agents (Kharbanda et al., 1995a
,b
). Like c-Abl, nuclear
Lyn activates MEKK-1 and contributes to activation of SAPK (Yoshida et
al., 2000
). In contrast to c-Abl, Lyn activates SAPK by an
MKK7-dependent, SEK1-independent mechanism (Yoshida et al., 2000
).
These findings have supported a model in which activation of SAPK in
the apoptotic response to DNA damage is mediated by both c-Abl and Lyn.
The present studies demonstrate that treatment of human U-937 leukemia
cells with ara-C is associated with activation of the c-Abl
SAPK
pathway and targeting of SAPK to mitochondria. The results show that
the c-Abl inhibitor, STI571, attenuates ara-C-induced SAPK activation
and SAPK to mitochondria localization. STI571 treatment also attenuated
loss of mitochondrial transmembrane potential, activation of caspase-3,
and induction of apoptosis in the response to ara-C.
| |
Materials and Methods |
|---|
|
|
|---|
Cell Culture.
Human U-937 myeloid leukemia cells (American
Type Culture Collection, Manassas, VA) were grown in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal bovine serum, 100 units/ml of penicillin, 100 mg/ml of streptomycin, and 2 mM
L-glutamine. Human MCF-7 breast cancer cells and wild-type
and c-Abl
/
mouse embryo fibroblasts (MEF)
were maintained in Dulbecco's modified Eagle's medium containing 10%
fetal bovine serum and antibiotics. Cells were treated with 10 mM ara-C
(Sigma-Aldrich, St. Louis, MO) or the indicated concentrations of
STI571 (Gleevec; Novartis, Basel, Switzerland).
Isolation of Mitochondrial and Nuclear Fractions.
Cells
(3 × 106) were washed twice with
phosphate-buffered saline (PBS), homogenized in buffer A (210 mM
mannitol, 70 mM sucrose, 1 mM EGTA, and 5 mM HEPES, pH 7.4) and 110 mg/ml of digitonin in a glass homogenizer (Pyrex 7727-07; Corning,
Acton, MA), and centrifuged at 5,000g for 20 min.
Pellets were resuspended in buffer A, homogenized in a small glass
homogenizer (Pyrex 7726), and centrifuged at 2,000g for 5 min. The supernatant was collected and centrifuged at
11,000g for 10 min. Mitochondrial pellets were disrupted in
lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet
P-40, 1 mM dithiothreitol, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, 10 mM NaF, and 10 mg/ml each of leupeptin and aprotinin) at 4°C and then centrifuged at
15,000g for 15 min. Protein concentration was determined by
Bio-Rad protein estimation kit (Bio-Rad, Hercules, CA). The nuclear
fraction was prepared as described previously (Kharbanda et al., 1996
).
Immunoblot Analysis.
Cell lysates and fractions were
subjected to immunoblotting with anti-c-Abl (24-11; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA), anti-SAPK (C-17; Santa Cruz
Biotechnology, Inc.), anti-HSP60 (Stressgen Biotechnologies Corp.,
Victoria, BC, Canada), anti-
-actin (Sigma-Aldrich), anti-PCNA
(Calbiochem, San Diego, CA), or anti-caspase-3 (Stressgen
Biotechnologies Corp.). The antigen-antibody complexes were visualized
by enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ).
Immunofluorescence Microscopy. Cells were plated onto poly-D-lysine-coated glass coverslips 1 day before ara-C treatment (1 h) and then fixed with 3.7% formaldehyde and PBS, pH 7.4, for 10 min. Cells were washed with PBS, permeabilized with 0.2% Triton X-100 for 10 min, washed again, and incubated for 30 min in complete medium. The coverslips were then incubated with 5 mg/ml anti-c-Abl (K-12; Santa Cruz Biotechnology, Inc.) or anti-SAPK (C-17) for 1 h followed by Texas Red goat anti-rabbit IgG (H&L regions) conjugate (Molecular Probes, Eugene, OR). Mitochondria were stained with 100 nM Mitotracker Green FM (Molecular Probes). Nuclei were stained with 4,6-diamino-2-phenylindole (1 mg/ml in PBS). Coverslips were mounted onto slides with 0.1 M Tris-HCl, pH 7.0, in 50% glycerol. Cells were visualized by digital confocal immunofluorescence, and images were captured with a CCD camera mounted on a Zeiss Axioplan 2 microscope (Zeiss, Welwyn Garden City, UK). Images were deconvolved using Slidebook software (Intelligent Imaging Innovations, Inc., Denver, CO).
Analysis of c-Abl and SAPK Activity.
Cell and nuclear
lysates were prepared in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1% Nonidet P-40, 1 mM dithiothreitol, 1 mM sodium orthovanadate,
1 mM phenylmethylsulfonyl fluoride, 10 mM NaF, and 10 mg/ml each of
leupeptin and aprotinin) and subjected to immunoprecipitation as
described previously (Kharbanda et al., 1997
) with anti-c-Abl (K-12)
or anti-SAPK (C-17). The immunoprecipitates were resuspended in kinase
buffer (20 mM HEPES, pH 7.4, and 10 mM each MgCl2
and MnCl2) containing 2.5 mCi of
[
-32P]ATP, GST-Crk(120-225),
GST-Crk(120-212), or GST-Jun for 20 min at 30°C. The reaction
products were analyzed by SDS-PAGE and autoradiography.
Analysis of Mitochondrial Membrane Potential. Cells were incubated with 50 ng/ml of Rhodamine 123 (Molecular Probes) for 15 min at 37°C. After washing with PBS, samples were analyzed by flow cytometry using 488-nm excitation and the measurement of emission through a 575/26 (ethidium) bandpass filter.
Assessment of Apoptosis. SubG1 DNA content was assessed by staining ethanol-fixed cells with propidium iodide and monitoring by FACScan (BD Biosciences, San Jose, CA).
| |
Results |
|---|
|
|
|---|
Ara-C Targets SAPK to Mitochondria.
To determine whether c-Abl
localizes to mitochondria in the DNA-damage response, mitochondrial
lysates from control and ara-C-treated U-937 cells were analyzed by
immunoblotting with anti-c-Abl. As shown previously (Ito et al.,
2001b
; Kumar et al., 2001
), c-Abl was detectable in mitochondria of
control cells (Fig. 1A). In contrast to
oxidative and endoplasmic reticulum (ER)-induced stress (Ito et al.,
2001b
; Kumar et al., 2001
), treatment of U-937 cells with ara-C had
little effect on mitochondrial c-Abl levels (Fig. 1A). Although c-Abl
functions as an upstream effector of SAPK in the ara-C response
(Kharbanda et al., 1995a
,b
, 2000
), immunoblot analyses were performed
to assess targeting of SAPK to mitochondria. In contrast to c-Abl, the
results show that ara-C induces a 3-fold increase in mitochondrial SAPK
levels at 2 h (Fig. 1A). Longer ara-C exposures (i.e., 6 h)
associated with the induction of U-937 cell apoptosis resulted in a
decline in SAPK signals (Fig. 1A). Equal loading of the lanes was
confirmed by immunoblot analysis of the mitochondrial HSP60 (Fig. 1A).
Purity of the mitochondrial fraction was confirmed by immunoblotting
with antibodies against the cytoplasmic
-actin protein and the
nuclear PCNA protein (Fig. 1A). There was no detectable
-actin or
PCNA in the mitochondrial fraction (Fig. 1A). To assess the effects of
ara-C in different cell types, studies were performed on MCF-7 breast
cancer cells. The results demonstrate that ara-C induces translocation
of SAPK, but not c-Abl, to mitochondria (Fig. 1B). Similar results were obtained in ara-C-treated MEFs (Fig. 1C).
|
yellow/orange) (Fig. 2B). These
findings and those obtained by immunoblotting demonstrate that SAPK,
and not c-Abl, is targeted to mitochondria in the cellular response to
ara-C.
|
STI571 Blocks Ara-C-Induced Activation of SAPK.
To determine
whether ara-C targets SAPK to mitochondria by a c-Abl-dependent
mechanism, U-937 cells were treated with ara-C and the c-Abl inhibitor
STI571 (Druker et al., 1996
). Anti-c-Abl immunoprecipitates from
nuclear lysates were analyzed for phosphorylation of GST-Crk(120-225)
and, as a control, GST-Crk(120-212), which lacks the c-Abl
phosphorylation site (Kharbanda et al., 1995b
). As shown previously
(Kharbanda et al., 1995b
), ara-C treatment is associated with induction
of nuclear c-Abl activity (Fig. 3A). Pretreatment of the cells with 0.1 or 1.0 µM STI571 resulted in only
partial inhibition of c-Abl activation in ara-C-treated cells (Fig.
3A). In contrast, treatment with 10 µM STI571 blocked ara-C-induced nuclear c-Abl activity (Fig. 3A). To assess the effects of STI571 on
ara-C-induced activation of SAPK, anti-SAPK immunoprecipitates were
analyzed for phosphorylation of c-Jun. The results demonstrate that, in
contrast to ara-C, treatment with STI571 alone has no apparent effect
on SAPK activity (Fig. 3B). Moreover, STI571 attenuated the induction
of SAPK activity by over 50% in ara-C-treated U-937 cells (Fig. 3B).
Similar findings were obtained in MCF-7 cells that were pretreated with
STI571 and then exposed to ara-C (Fig. 3C).
|
STI571 Inhibits Ara-C-Induced Targeting of SAPK to
Mitochondria.
To determine whether STI571 affects mitochondrial
targeting of SAPK, studies were performed on STI571- and STI571 + ara-C-treated U-937 cells (Fig. 4A). The
results demonstrate that STI571 alone has no apparent effect on the
mitochondrial distribution of SAPK compared with that in untreated
cells (Fig. 4A). Moreover, in contrast to ara-C-treated cells,
targeting of SAPK to mitochondria was attenuated by STI571 treatment
(Fig. 4A). As a control, similar studies were performed on MEFs that
were deficient in c-Abl expression. Compared with that in wild-type
MEFs, ara-C-induced targeting of SAPK to mitochondria was attenuated
in c-Abl
/
MEFs (Fig. 4B). These results
indicate that STI571 blocks c-Abl-dependent mitochondrial targeting of
SAPK in the ara-C response.
|
STI571 Attenuates Ara-C-Induced Loss of Mitochondrial
Transmembrane Potential, Caspase-3 Activation, and Apoptosis.
To
determine whether activation of the c-Abl
SAPK pathway contributes
to loss of mitochondrial transmembrane potential (
m), wild-type
MEFs were treated with ara-C and then stained with Rhodamine 123. The
results demonstrate that ara-C treatment is associated with a decrease
in 
m (Fig. 5A). Moreover, although
STI571 alone had no effect on 
m, STI571 pretreatment attenuated
this response to ara-C (Fig. 5A). As a control, the response of
c-Abl
/
MEFs to ara-C was associated with an
attenuated loss of 
m compared with that found with wild-type MEFs
(Fig. 5B).
|
/
cells treated with ara-C (Fig. 6C, bottom). In concert with these results, ara-C-induced apoptosis was attenuated in
c-Abl
/
MEFs (Fig. 6D). These results
demonstrate that inhibition of c-Abl
SAPK signaling with STI571
attenuates ara-C-induced loss of 
m, activation of caspase-3, and
apoptosis.
|
| |
Discussion |
|---|
|
|
|---|
Eukaryotic cells respond to DNA damage with cell cycle arrest,
activation of DNA repair, and, in the event of irreparable damage,
induction of apoptosis. The signals that determine cell fate (that is,
repair of DNA damage and survival versus activation of cell death
mechanisms) remain unclear. Exposure of diverse types of mammalian
cells to ara-C and other DNA-damaging agents is associated with the
induction of SAPK activity (Kharbanda et al., 1995a
,b
; Chen et al.,
1996
; Verheij et al., 1996
; Zanke et al., 1996
). Induction of SAPK in
the response to genotoxic stress is associated with activation of c-Jun
and transcription of the c-jun gene (Kharbanda et al., 1990
; Sherman et
al., 1990
). The functional significance of c-jun transcription is
presumably related to the activation of later response genes that
determine cell fate. In this context, activation of SAPK in the
response to DNA damage has been associated with induction of apoptosis
(Chen et al., 1996
; Verheij et al., 1996
; Zanke et al., 1996
).
Moreover, direct evidence for involvement of SAPK in the induction of
apoptosis has been obtained from studies in SAPK-deficient MEFs
(Tournier et al., 2000
). SAPK is required for UV-induced apoptosis, and the absence of SAPK causes a defect in the mitochondrial death signaling pathway (Tournier et al., 2000
). These findings indicate that, in addition to activation of early response genes, the SAPK pathway confers proapoptotic signals to mitochondria.
Certain insights into how DNA damage is converted into intracellular
signals that induce an apoptotic response have been obtained from the
finding that a nuclear complex of the c-Abl and Lyn tyrosine kinases is
activated by ara-C and other genotoxic agents (Kharbanda et al., 1994
,
1995a
,b
; Yuan et al., 1995
). Activation of the Lyn
MEKK-1
MKK7
SAPK pathway contributes to the induction of apoptosis by
DNA-damaging agents (Yoshida et al., 2000
). c-Abl also functions in
DNA-damage-induced activation of SAPK but by a mechanism involving the
c-Abl
MEKK1
SEK1
SAPK pathway (Kharbanda et al., 1995a
,
2000a
). In contrast, other studies have suggested that SAPK functions
upstream to c-Abl activation (Dan et al., 1999
). Although the basis for
a SAPK
c-Abl signaling cascade is not clear (Dan et al., 1999
),
we asked whether activation of the c-Abl
SAPK pathway transduces
proapoptotic signals in the response to DNA damage. The present studies
demonstrate that treatment of U-937 leukemia cells with ara-C is
associated with targeting of SAPK, and not c-Abl, to mitochondria.
Similar results were obtained in other cell types, suggesting that the
findings are broadly applicable to the genotoxic stress response. In
this context, treatment of cells with ionizing radiation is also
associated with mitochondrial targeting of SAPK and not c-Abl
(Kharbanda et al., 2000b
). These findings are in contrast to the
demonstration that cytoplasmic c-Abl localizes to mitochondria in the
cell death response of cells to oxidative stress (Sun et al., 2000
;
Kumar et al., 2001
). Moreover, ER-associated c-Abl is targeted to
mitochondria in the apoptotic response of cells to ER stress (Ito et
al., 2001b
). Thus, signaling of nuclear c-Abl in the DNA-damage
response differs from that found for targeting of c-Abl to mitochondria
with other types of stress.
Experiments were performed with the c-Abl inhibitor, STI571 (Druker et
al., 1996
), to assess the role of c-Abl in DNA-damage-induced targeting
of SAPK to mitochondria. STI571 has exceptionally high affinity and
specificity for Bcr-Abl and c-Abl (Buchdunger et al., 1996
). Activation
of nuclear c-Abl by ara-C was completely inhibited with 10 mM STI571.
These findings are in concert with the demonstration that STI571
exhibits a Ki value of 7 mM for the
tyrosine-phosphorylated or -activated form of c-Abl (Schindler et al.,
2000
). Other studies have shown that STI571 inhibits c-Abl activation
in cells treated with the genotoxic agent etoposide (Dan et al., 1999
).
Our findings with ara-C differ, however, in that STI571 has no effect
on SAPK activation in the response of U-937 cells to etoposide (Dan et
al., 1999
). In the present studies, STI571 inhibited ara-C-induced
SAPK activation, but, consistent with involvement of both c-Abl and
Lyn, failed to completely abrogate this response. STI571 also
attenuated targeting of SAPK to mitochondria in the response to ara-C.
In concert with the finding that SAPK transduces mitochondrial death
signals (Tournier et al., 2000
), STI571 blocked ara-C-induced loss of
mitochondrial transmembrane potential. Although other studies have
shown that loss of 
m is not required for activation of caspases
(Li et al., 2000
), our results demonstrate that STI571 also inhibits
ara-C-induced activation of caspase-3 and apoptosis. STI571 has also
been shown to inhibit the platelet-derived growth factor receptor and
c-kit (proto-oncogene tyrosine-protein kinase kit) (Carroll et
al., 1997
). Consequently, we performed studies with c-Abl-deficient MEFs to confirm whether c-Abl activation is responsible for transducing ara-C-induced proapoptotic signals to mitochondria. Taken together with the results from c-Abl
/
cells, the
findings with STI571 support a model in which activation of c-Abl
contributes, at least in part, to targeting proapoptotic signals to
mitochondria in genotoxic stress.
| |
Acknowledgments |
|---|
We are grateful to Kamal Chauhan for excellent technical support.
| |
Footnotes |
|---|
Received December 13, 2001; Accepted March 11, 2002
This investigation was supported by National Cancer Institute grant CA29431.
Address correspondence to: Dr. Donald Kufe, Dana-Farber Cancer Institute, 44 Binney St. #830, Boston, MA 02115. E-mail: donald_kufe{at}dfci.harvard.edu
| |
Abbreviations |
|---|
Ara-C, 1-
-D-arabinofuranosylcytosine;
SAPK, stress-activated
protein kinase;
MEF, mouse embryo fibroblast;
STI571, imatinib mesylate (Gleevec);
PBS, phosphate-buffered saline;
PCNA, proliferating cell
nuclear antigen;
HSP, heat shock protein;
CCD, charge-coupled device;
PAGE, polyacrylamide gel electrophoresis;
GST, glutathione
S-transferase;

m, mitochondrial transmembrane
potential;
MEKK-1, mitogen-activated protein kinase kinase kinase 1;
ER, endoplasmic reticulum.
| |
References |
|---|
|
|
|---|
-D-arabinofuranosylcytosine and other DNA damaging agents.
Blood
88:
1936-1943
-D-arabinofuranosylcytosine. Potential involvement of a protein kinase C dependent mechanism.
Biochemistry
30:
7947-7952[CrossRef][Medline].
-D-arabinofuranosylcytosine.
J Biol Chem
270:
30278-30281
-D-arabinofuranosyl)cytosine.
Biochemistry
32:
9137-9142[CrossRef][Medline].
-D-arabinofuranosylcytosine and other DNA-damaging agents.
Cell Growth Differ
6:
1651-1658[Abstract].
-D-arabinofuranosylcytosine activates the Src-like p56/p53lyn tyrosine kinase in human myeloid leukemia cells.
Biochemistry
34:
1058-1063[CrossRef][Medline].This article has been cited by other articles:
![]() |
L. J. Martin, Z. Liu, J. Pipino, B. Chestnut, and M. A. Landek Molecular Regulation of DNA Damage-Induced Apoptosis in Neurons of Cerebral Cortex Cereb Cortex, June 1, 2009; 19(6): 1273 - 1293. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Han, K. W. Chung, H. G. Cheon, S. D. Rhee, C.-H. Yoon, M.-K. Lee, K.-W. Kim, and M.-S. Lee Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes in db/db Mice Diabetes, February 1, 2009; 58(2): 329 - 336. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hagerkvist, S. Sandler, D. Mokhtari, and N. Welsh Amelioration of diabetes by imatinib mesylate (Gleevec(R)): role of {beta}-cell NF-{kappa}B activation and anti-apoptotic preconditioning FASEB J, February 1, 2007; 21(2): 618 - 628. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Thottassery, L. Westbrook, H. Someya, and W. B. Parker c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-{beta}-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. Mol. Cancer Ther., February 1, 2006; 5(2): 400 - 410. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Raina, P. Pandey, R. Ahmad, A. Bharti, J. Ren, S. Kharbanda, R. Weichselbaum, and D. Kufe c-Abl Tyrosine Kinase Regulates Caspase-9 Autocleavage in the Apoptotic Response to DNA Damage J. Biol. Chem., March 25, 2005; 280(12): 11147 - 11151. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Waxman and P. S. Schwartz Harnessing Apoptosis for Improved Anticancer Gene Therapy Cancer Res., December 15, 2003; 63(24): 8563 - 8572. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. Rao and W. Plunkett Activation of a p53-mediated Apoptotic Pathway in Quiescent Lymphocytes after the Inhibition of DNA Repair by Fludarabine Clin. Cancer Res., August 1, 2003; 9(8): 3204 - 3212. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Huang, Y. Wang, S. B. Cogut, B. S. Mitchell, and L. M. Graves Inhibition of Nucleoside Transport by Protein Kinase Inhibitors J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 753 - 760. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||